These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 30683146)

  • 1. The Evaluation of Vitiligous lesions Repigmentation after the Administration of Atorvastatin calcium salt and Simvastatin-acid sodium salt in patients with active vitiligo (EVRAAS), a pilot study: study protocol for a randomized controlled trial.
    Niezgoda A; Winnicki A; Kosmalski T; Kowaliszyn B; Krysiński J; Czajkowski R
    Trials; 2019 Jan; 20(1):78. PubMed ID: 30683146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topical application of simvastatin acid sodium salt and atorvastatin calcium salt in vitiligo patients. Results of the randomized, double-blind EVRAAS pilot study.
    Niezgoda A; Winnicki A; Krysiński J; Niezgoda P; Nowowiejska L; Czajkowski R
    Sci Rep; 2024 Jun; 14(1):14612. PubMed ID: 38918590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing effectiveness of adding niosomal atorvastatin 1% ointment to topical calcineurin inhibitor treatment in non-segmental vitiligo.
    Zartab H; Aflatoonian M; Shamsi-Meymandi S; Pardakhty A; Isazadeh A; Firooz A; Amiri R
    J Cosmet Dermatol; 2024 Jun; 23(6):2103-2108. PubMed ID: 38348697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, double-blind clinical trial to evaluate the efficacy of topical tacalcitol and sunlight exposure in the treatment of adult nonsegmental vitiligo.
    Rodríguez-Martín M; García Bustínduy M; Sáez Rodríguez M; Noda Cabrera A
    Br J Dermatol; 2009 Feb; 160(2):409-14. PubMed ID: 19016706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Tacrolimus 0.1% for the Treatment of Facial Vitiligo: A Multicenter Randomized, Double-Blinded, Vehicle-Controlled Study.
    Seneschal J; Duplaine A; Maillard H; Passeron T; Andreu N; Lassalle R; Favary C; Droitcourt C; Taïeb A; Ezzedine K
    J Invest Dermatol; 2021 Jul; 141(7):1728-1734. PubMed ID: 33549606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ginkgo biloba for the treatment of vitilgo vulgaris: an open label pilot clinical trial.
    Szczurko O; Shear N; Taddio A; Boon H
    BMC Complement Altern Med; 2011 Mar; 11():21. PubMed ID: 21406109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo.
    Rosmarin D; Passeron T; Pandya AG; Grimes P; Harris JE; Desai SR; Lebwohl M; Ruer-Mulard M; Seneschal J; Wolkerstorfer A; Kornacki D; Sun K; Butler K; Ezzedine K;
    N Engl J Med; 2022 Oct; 387(16):1445-1455. PubMed ID: 36260792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does topical tacrolimus ointment enhance the efficacy of narrowband ultraviolet B therapy in vitiligo? A left-right comparison study.
    Majid I
    Photodermatol Photoimmunol Photomed; 2010 Oct; 26(5):230-4. PubMed ID: 20831696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of interleukin-10 levels in lesions of vitiligo following treatment with topical tacrolimus.
    Taher ZA; Lauzon G; Maguiness S; Dytoc MT
    Br J Dermatol; 2009 Sep; 161(3):654-9. PubMed ID: 19438859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pimecrolimus cream in repigmentation of vitiligo.
    Seirafi H; Farnaghi F; Firooz A; Vasheghani-Farahani A; Alirezaie NS; Dowlati Y
    Dermatology; 2007; 214(3):253-9. PubMed ID: 17377388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simvastatin versus atorvastatin for improving mild to moderate depression in post-coronary artery bypass graft patients: A double-blind, placebo-controlled, randomized trial.
    Abbasi SH; Mohammadinejad P; Shahmansouri N; Salehiomran A; Beglar AA; Zeinoddini A; Forghani S; Akhondzadeh S
    J Affect Disord; 2015 Sep; 183():149-55. PubMed ID: 26005776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simvastatin prevents and reverses depigmentation in a mouse model of vitiligo.
    Agarwal P; Rashighi M; Essien KI; Richmond JM; Randall L; Pazoki-Toroudi H; Hunter CA; Harris JE
    J Invest Dermatol; 2015 Apr; 135(4):1080-1088. PubMed ID: 25521459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microdermabrasion and topical tacrolimus: A novel combination therapy of vitiligo.
    Abd-Elazim NE; Yassa HA; Mahran AM
    J Cosmet Dermatol; 2020 Jun; 19(6):1447-1455. PubMed ID: 31668003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response of vitiligo to once- vs. twice-daily topical tacrolimus: a controlled prospective, randomized, observer-blinded trial.
    Radakovic S; Breier-Maly J; Konschitzky R; Kittler H; Sator P; Hoenigsmann H; Tanew A
    J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):951-3. PubMed ID: 19496898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time-kinetic study of repigmentation in vitiligo patients by tacrolimus or pimecrolimus.
    Lubaki LJ; Ghanem G; Vereecken P; Fouty E; Benammar L; Vadoud-Seyedi J; Dell'Anna ML; Briganti S; Picardo M; Heenen M
    Arch Dermatol Res; 2010 Mar; 302(2):131-7. PubMed ID: 19547993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maintenance therapy of adult vitiligo with 0.1% tacrolimus ointment: a randomized, double blind, placebo-controlled study.
    Cavalié M; Ezzedine K; Fontas E; Montaudié H; Castela E; Bahadoran P; Taïeb A; Lacour JP; Passeron T
    J Invest Dermatol; 2015 Apr; 135(4):970-974. PubMed ID: 25521460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tacrolimus ointment 0.1% produces repigmentation in patients with vitiligo: results of a prospective patient series.
    Tanghetti EA
    Cutis; 2003 Feb; 71(2):158-62. PubMed ID: 12635898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic effects of turmeric topical cream in vitiligo: A randomized, double-blind, placebo-controlled pilot study.
    Jalalmanesh S; Mansouri P; Rajabi M; Monji F
    J Cosmet Dermatol; 2022 Oct; 21(10):4454-4461. PubMed ID: 35104042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of ruxolitinib cream 1.5% as an at-home therapy for repigmentation in non-segmental vitiligo.
    Agner ML; Parraga SP; Arkhipenko ZM; Pichardo RO; McMichael AJ; Feldman SR
    Expert Rev Clin Immunol; 2024 Jul; 20(7):695-702. PubMed ID: 38879876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topical Histamine Stimulates Repigmentation of Nonsegmental Vitiligo by a Receptor-Dependent Mechanism.
    Liu J; Xu Y; Lin TK; Lv C; Elias PM; Man MQ
    Skin Pharmacol Physiol; 2017; 30(3):139-145. PubMed ID: 28419984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.